Efficacy and safety of puerarin injection in curing acute ischemic stroke

Abstract

Background:Previous studies indicated that the puerarin injection has been widely employed in China for the treatment of acute ischemic stroke. We aim to evaluate the efficacy and safety of the puerarin injection for the treatment of acute ischemic stroke.Methods:A systematic literature search was performed in PUBMED, EMBASE, SPRINGER LINK, Scopus, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Journals Database, Wanfang database and the China Biological Medicine database before November 2016, randomized controlled clinical trials (RCTs) of puerarin injection treating acute ischemic stroke were included. In addition, we searched reference lists of relevant retrieved articles. Two authors extracted data independently. The effective rate, the neurologic deficit score, the blood rheology indexes, and fibrinogen were assessed and analyzed by the Review Manager 5.3 software. The continuous variables were expressed as MD with 95% CI and dichotomous data used RR or ORs. Adverse reactions related to the puerarin injection were also examined.Results:Thirty-five RCTs with a total of 3224 participants were identified in the meta-analysis. The combined results of 32 trials indicated that the puerarin injection was better than control drugs at the clinical effective rate (RR 1.22, 95% CI 1.17 to 1.28, P < 0.001) and 16 studies showed the neurological deficit was significantly improved (MD –3.69, 95% CI –4.67 to –2.71, P < 0.001); the hemorheology index and fibrinogen were much lower with the puerarin injection when compared with western conventional medicines (WCM) or other control drugs (the whole blood viscosity: MD –0.89, 95% CI –1.37 to –0.41, P < 0.001; the HCT: MD –0.04, 95% CI –0.06 to –0.02, P < 0.001; the fibrinogen: MD –0.64, 95% CI –0.96 to –0.31, P < 0.001). Eleven trials reported that the adverse reactions related to the puerarin injection included facial flushing, dizziness, vomiting, nausea, and other mild gastrointestinal discomfort and allergic reaction. No serious adverse drug reactions were reported.Conclusions:Puerarin injection may be more effective and relatively safe in clinic for treating acute ischemic stroke. However, the current evidence is insufficient due to the poor methodological quality and lack of adequate safety data. Further RCTs are required to examine its efficacy.

Agranulocytosis Induced by Sinomenine Hydrochloride

“…Recent reports of adverse events associated with Chinese herbal medicines have increased [ 7 ]. For example, the use of herbal remedies containing aristolochic acid has recently been banned in China due to the association with renal toxicity and carcinogenicity [ 8 ].…”

Therapeutic potential of glutathione-enhancers in stress-related psychopathologies

“…L-carnitine has been shown to lack side effects in humans at doses up to 7 g/kg per day for seven days (Cruciani, Dvorkin et al 2006) and in similar doses even for up to 2 months (Curran, Morhart et al 2019). Regarding puerarin, a recent meta-analysis has suggested that treatment with up to 500 mg of puerarin per day for 2-3 weeks was not accompanied by severe side effects, while doses of 200 mg have been shown potential in improving the neurological condition following traumatic brain injury (Zheng, Li et al 2017).…”

Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling

“…evaluated the efficacy and safety of the puerarin injection for the treatment of acute ischemic stroke. They reported that puerarin injection could improve the neurological deficit and decrease the hemorheology index and fibrinogen in patients with acute ischemic stroke [ 153 ]. Their study suggests that puerarin injection may be effective and relatively safe in the clinic for treating acute ischemic stroke [ 153 ].…”